Literature DB >> 35253557

Defining cognitive impairment in amyotrophic lateral sclerosis: an evaluation of empirical approaches.

Corey T McMillan1, Joanne Wuu2, Katya Rascovsky1, Stephanie Cosentino3, Murray Grossman1, Lauren Elman1, Colin Quinn1, Luis Rosario1, Jessica H Stark2, Volkan Granit2, Hannah Briemberg4, Sneha Chenji5, Annie Dionne6, Angela Genge7, Wendy Johnston8, Lawrence Korngut5, Christen Shoesmith9, Lorne Zinman10, Sanjay Kalra8,11, Michael Benatar2.   

Abstract

Objective: Amyotrophic lateral sclerosis (ALS) is a multi-system disorder characterized primarily by motor neuron degeneration, but may be accompanied by cognitive dysfunction. Statistically appropriate criteria for establishing cognitive impairment (CI) in ALS are lacking. We evaluate quantile regression (QR), that accounts for age and education, relative to a traditional two standard deviation (SD) cutoff for defining CI.
Methods: QR of cross-sectional data from a multi-center North American Control (NAC) cohort of 269 healthy adults was used to model the 5th percentile of cognitive scores on the Edinburgh Cognitive and Behavioral ALS Screen (ECAS). The QR approach was compared to traditional two SD cutoff approach using the same NAC cohort (2SD-NAC) and to existing UK-based normative data derived using the 2SD approach (2SD-UK) to assess the impact of cohort selection and statistical model in identifying CI in 182 ALS patients.
Results: QR-NAC models revealed that age and education impact cognitive performance on the ECAS. Based on QR-NAC normative cutoffs, the frequency of CI in the 182 PENN ALS patients was 15.9% for ALS specific, 12.6% for ALS nonspecific, and 15.4% for ECAS total. This frequency of CI is substantially more conservative in comparison to the 2SD-UK (20.3%-34.6%) and modestly more conservative to the 2SD-NAC (14.3%-16.5%) approaches for estimating CI. Conclusions: The choice of normative cohort has a substantial impact and choice of statistical method a modest impact on defining CI in ALS. This report establishes normative ECAS thresholds to identify whether ALS patients in the North American population have CI.

Entities:  

Keywords:  ALS-FTD; Cognition; ECAS; biomarker; dementia; neuropsychology; normative data; risk

Year:  2022        PMID: 35253557      PMCID: PMC9448823          DOI: 10.1080/21678421.2022.2039713

Source DB:  PubMed          Journal:  Amyotroph Lateral Scler Frontotemporal Degener        ISSN: 2167-8421            Impact factor:   3.528


  36 in total

Review 1.  El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis.

Authors:  B R Brooks; R G Miller; M Swash; T L Munsat
Journal:  Amyotroph Lateral Scler Other Motor Neuron Disord       Date:  2000-12

2.  Deficits in concept formation in amyotrophic lateral sclerosis.

Authors:  David J Libon; Corey McMillan; Brian Avants; Ashley Boller; Brianna Morgan; Lisa Burkholder; Keerthi Chandrasekaran; Lauren Elman; Leo McCluskey; Murray Grossman
Journal:  Neuropsychology       Date:  2012-05-21       Impact factor: 3.295

3.  Microglial activation and TDP-43 pathology correlate with executive dysfunction in amyotrophic lateral sclerosis.

Authors:  Johannes Brettschneider; David J Libon; Jon B Toledo; Sharon X Xie; Leo McCluskey; Lauren Elman; Felix Geser; Virginia M Y Lee; Murray Grossman; John Q Trojanowski
Journal:  Acta Neuropathol       Date:  2012-01-01       Impact factor: 17.088

4.  Derivation of norms for the Dutch version of the Edinburgh cognitive and behavioral ALS screen.

Authors:  Leonhard A Bakker; Carin D Schröder; Lauriane A Spreij; Marianne Verhaegen; Joke De Vocht; Philip Van Damme; Jan H Veldink; Johanna M A Visser-Meily; Leonard H van den Berg; Tanja C W Nijboer; Michael A van Es
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2018-10-12       Impact factor: 4.092

5.  Relation of neuropsychological and magnetic resonance findings in amyotrophic lateral sclerosis: evidence for subgroups.

Authors:  B Frank; J Haas; H J Heinze; E Stark; T F Münte
Journal:  Clin Neurol Neurosurg       Date:  1997-05       Impact factor: 1.876

6.  Narrative discourse deficits in amyotrophic lateral sclerosis.

Authors:  Sharon Ash; Anna Menaged; Christopher Olm; Corey T McMillan; Ashley Boller; David J Irwin; Leo McCluskey; Lauren Elman; Murray Grossman
Journal:  Neurology       Date:  2014-07-02       Impact factor: 9.910

Review 7.  Changes in cognition and behaviour in amyotrophic lateral sclerosis: nature of impairment and implications for assessment.

Authors:  Laura H Goldstein; Sharon Abrahams
Journal:  Lancet Neurol       Date:  2013-03-18       Impact factor: 44.182

8.  The Edinburgh Cognitive and Behavioral ALS screen: relationship to age, education, IQ and the Addenbrooke's Cognitive Examination-III.

Authors:  Mónica M De Icaza Valenzuela; Thomas H Bak; Suvankar Pal; Sharon Abrahams
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2018-10-29       Impact factor: 4.092

9.  Automated analysis of natural speech in amyotrophic lateral sclerosis spectrum disorders.

Authors:  Naomi Nevler; Sharon Ash; Corey McMillan; Lauren Elman; Leo McCluskey; David J Irwin; Sunghye Cho; Mark Liberman; Murray Grossman
Journal:  Neurology       Date:  2020-07-16       Impact factor: 9.910

10.  Machine learning suggests polygenic risk for cognitive dysfunction in amyotrophic lateral sclerosis.

Authors:  Katerina Placek; Michael Benatar; Joanne Wuu; Evadnie Rampersaud; Laura Hennessy; Vivianna M Van Deerlin; Murray Grossman; David J Irwin; Lauren Elman; Leo McCluskey; Colin Quinn; Volkan Granit; Jeffrey M Statland; Ted M Burns; John Ravits; Andrea Swenson; Jon Katz; Erik P Pioro; Carlayne Jackson; James Caress; Yuen So; Samuel Maiser; David Walk; Edward B Lee; John Q Trojanowski; Philip Cook; James Gee; Jin Sha; Adam C Naj; Rosa Rademakers; Wenan Chen; Gang Wu; J Paul Taylor; Corey T McMillan
Journal:  EMBO Mol Med       Date:  2020-12-03       Impact factor: 14.260

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.